The North America digital pathology market size is expected to reach USD 693.9 million in 2030 and is expected to grow at a CAGR of 7.8% from 2025 to 2030. The market is predominantly driven by the growing prevalence of chronic diseases such as cancer. As a consequence of the high prevalence of cancer, pathologists require data that facilitate personalizing therapy for patients. Hence, digital pathology is progressively being selected by pathologists as it has various benefits including accelerated diagnosis rate, diagnostic accuracy, and offers therapeutic recommendations to improve patient outcomes.
The growing number of collaborative agreements to develop as well as expedite the adoption of digital pathology in cancer diagnostics serves as a key growth factor contributing to the market. The use of artificial intelligence in digital pathology has gained momentum in the past years. The increasing need for lowering healthcare costs, increasing importance of big data in healthcare, rising adoption of precision medicine, and declining hardware costs are some factors driving the growth. In addition, increasing usage of artificial intelligence-based analytical tools in healthcare and high capital investments in this field are further propelling the market growth.
During the coronavirus outbreak, the exponential need for home-based workstations and safe clinical informatics systems allowing healthcare professionals to read images remotely and enabling virtual collaboration between their multi-disciplinary care teams has increased. Various histopathology departments in the region faced a reducing workforce and increasing workload during the pandemic. Digital pathology considered being the potential solution for some of the challenges faced by the pathologist, there is an increase in the adoption of digital diagnosis of disease during coronavirus outbreak.
In April 2020, Philips announced that the FDA granted a waiver for home use of consumer monitors with the company's IntelliSite Pathology Solution during the emergency. The temporary exemption of restrictions on remote use of the digital pathology helps pathologists to access whole slide images from home and fasten the diagnosis of histology cases. Some pathology labs that have adopted DP in their workflows across different sites pre-COVID-19, reported improved collaboration, and an average productivity gain of 21.0% with operation efficiency increased by 13.0%. These types of initiatives are anticipated to fuel market growth.
Request a free sample copy or view report summary: North America Digital Pathology Market Report
North America digital pathology market is currently experiencing significant growth, at an accelerating pace
The device segment held the largest share of 52.07% in 2024
The human pathology segment held the largest share in 2024
The academic research segment dominated the market in 2024he forecast period
The digital pathology market in the U.S. dominated the regional market with the largest share in 2024
Grand View Research has segmented the North America digital pathology market report based on product, application, type, end-use, and country:
North America Digital Pathology Product Outlook (Revenue, USD Billion, 2018 - 2030)
Software
Device
Scanners
Slide Management System
Storage System
North America Digital Pathology Type Outlook (Revenue, USD Billion, 2018 - 2030)
Human Pathology
Veterinary Pathology
North America Digital Pathology Application Outlook (Revenue, USD Billion, 2018 - 2030)
Drug Discovery & Development
Academic Research
Disease Diagnosis
Cancer Cell Detection
Others
North America Digital Pathology End-use Outlook (Revenue, USD Billion, 2018 - 2030)
Hospitals
Biotech & Pharma Companies
Diagnostic Labs
Academic & Research Institutes
North America Digital Pathology Country Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
List of Key Players in the North America Digital Pathology Market
Leica Biosystems Nussloch GmbH (Danaher)
Hamamatsu Photonics, Inc
Koninklijke Philips N.V.
Olympus Corporation
F. Hoffmann-La Roche Ltd
Mikroscan Technologies, Inc
Inspirata, Inc.
Epredia (3DHISTECH Ltd.)
Huron Technologies International Inc.
CellaVision
Morphle Labs, Inc
Bionovation Biotech, Inc
"The quality of research they have done for us has been excellent..."